Launched in January 2023, the “enhanced Ribosome Innovations” (eRIs) initiative is a public-private experience stemming from the collaboration between the Institute of Biophysics (CNR, Italy) and Immagina Biotechnology s.r.l. eRIs represents a unique milieu that experiments with cutting-edge technologies to develop next-gen solutions and dissect translational landscapes at ultrahigh resolution.
In parallel, eRIs leverages these technologies to discover and develop RNA- and translation-based biomarkers of devastating diseases. eRIs' ultimate mission is to fill the gaps in medical care and counselling practices, meeting and anticipating clinicians and patients’ expectations.
RiboMe - analysis of the RNA 2'-O-methylome
At Immagina Biotech, we believe that truly innovative tools have the power to reshape the boundaries of RNA discovery. While many commercial kits follow established paths, our goal is to pave new ones. From ribosome profiling to epitranscriptomics, we design and develop pioneering products like RiboMe—the first commercial kit for standardized analysis of the RNA 2’-O-methylome. Even when specific applications are just beginning to emerge, we invest in technologies that open up untapped molecular layers. With every new tool, we invite scientists to explore what biology has been hiding. Because at Immagina, “Imagine what you can discover” isn’t just a tagline—it’s a commitment to enabling the future of RNA research.